Improved clinical response from neoadjuvant taxane chemotherapy across breast cancer subtypes.

@article{Jenkins2009ImprovedCR,
  title={Improved clinical response from neoadjuvant taxane chemotherapy across breast cancer subtypes.},
  author={Emily O Jenkins and Allison M Deal and Emily M Burrows and Amy A Drobish and Lisa A. Carey},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={576}
}
576 Background: Adjuvant trials suggest that taxane (T) after doxorubicin and cyclophosphamide (AC) has little benefit in hormone receptor positive (HR+) patients compared to hormone receptor negative (HR-) patients, particularly if HER2 negative. Primary chemotherapy sensitivity is best determined from the neoadjuvant setting, therefore we sought to determine if HR+ primary tumors are less sensitive to taxane chemotherapy than HR- tumors. METHODS Clinical stage II-III breast cancer patients… CONTINUE READING